Stockscreener 앱 받기
26.95
11.20%
-3.40
시간 외 거래:
26.50
-0.45
-1.67%
Instil Bio Inc 주식(TIL)의 최신 뉴스
Instil Bio (TIL) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Wall Street Analysts Believe Instil Bio (TIL) Could Rally 343.63%: Here's is How to Trade - MSN
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference - The Manila Times
Instil Bio CEO Reveals Latest Pipeline Updates at Prestigious Jefferies Healthcare Conference - Stock Titan
Instil Bio Elects Director and Ratifies Auditor - TipRanks
Instil Bio Advances Phase 2 Trial in China - TipRanks
(TIL) Proactive Strategies - news.stocktradersdaily.com
Instil Bio: Second Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success (TIL) - Seeking Alpha
H.C. Wainwright lifts Instil Bio stock target to $125 By Investing.com - Investing.com South Africa
H.C. Wainwright lifts Instil Bio stock target to $125 - Investing.com
Instil Bio (TIL) Receives Price Target Upgrade by HC Wainwright & Co. | TIL Stock News - GuruFocus
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following P - GuruFocus
Instil Bio and ImmuneOnco to Host Investor and Analyst - GlobeNewswire
Instil Bio and ImmuneOnco Announce Joint Investor Breakfast in Chicago to Discuss Immuno-Oncology Developments - Nasdaq
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving ... - Bluefield Daily Telegraph
H.C. Wainwright Boosts Instil Bio (TIL) Price Target Following Positive Data Release | TIL Stock News - GuruFocus
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | - GuruFocus
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in - GlobeNewswire
Instil Bio (TIL) Shares Surge on New Clinical Development Plans - GuruFocus
Instil Bio stock rises on cancer trial updates (TIL:NASDAQ) - Seeking Alpha
Instil Bio (TIL) Maintains Buy Rating as Price Target is Adjusted | TIL Stock News - GuruFocus
Instil Bio stock price target cut to $105 by H.C. Wainwright - Investing.com Nigeria
Instil Bio (TIL) Price Target Reduced by Analyst | TIL Stock News - GuruFocus
Instil Bio Partners with ImmuneOnco for Cancer Therapy - TipRanks
Instil Bio (TIL) Advances Clinical Trials for NSCLC Treatment | TIL Stock News - GuruFocus
Alerts incorrectly tagged to T Rowe Price Large-Cap Value Fund withdrawn - marketscreener.com
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 ... - Bluefield Daily Telegraph
Instil Bio's Lung Cancer Drug Achieves 23% Response Rate in Phase 2 Trial, Major Results Expected in Late 2025 - Stock Titan
Pre-market Movers: NRXS, EYEN, TIL, HCTI, EKSO... - RTTNews
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Pegasystems Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
(TIL) Investment Analysis - news.stocktradersdaily.com
Instil (TIL) Projects Financial Stability Through 2026 | TIL Sto - GuruFocus
Instil Bio, Inc. SEC 10-Q Report - TradingView
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Instil Bio Inc expected to post a loss of $2.59 a shareEarnings Preview - TradingView
Trading (TIL) With Integrated Risk Controls - news.stocktradersdaily.com
Financial Metrics Check: Microbot Medical Inc (MBOT)’s Ratios for Trailing Twelve Months - DWinneX
Investor’s Toolkit: Key Ratios for Assessing Instil Bio Inc (TIL)’s Performance - DWinneX
TIL’s Stock Market Adventure: -33.05% YTD Growth Amidst Volatility - investchronicle.com
Have you been able to find a good deal on Instil Bio Inc’s shares? - uspostnews.com
Instil Bio Inc (TIL) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
(TIL) Trading Report - news.stocktradersdaily.com
Here's Why Summit Therapeutics Stock Soared 15% on Friday - Nasdaq
GT’s Debt-to-Equity Ratio at 1.85: What It Means for Goodyear Tire & Rubber Co’s Future - investchronicle.com
Where are the Opportunities in (TIL) - news.stocktradersdaily.com
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market Report 2025: 75+ Therapies are Under Development and 100+ Clinical Trials are Underway Globally - GlobeNewswire Inc.
Tumor-infiltrating Lymphocyte (TIL) Therapies Global Market - GlobeNewswire
SEC Form 424B5 filed by Instil Bio Inc. - Quantisnow
(TIL) Technical Pivots with Risk Controls - news.stocktradersdaily.com
The Significance of Moving Averages in New Found Gold Corp Inc. (NFGC) Price Performance - investchronicle.com
Instil Bio, Inc. SEC 10-K Report - TradingView
Instil Bio Reports 2024 Financial Results and Outlook - TipRanks
1.89%
3.74%
자본화:
|
볼륨(24시간):